Scientific Advisory Board

The Scientific Advisory Board is the external monitoring body and is composed of prof. Charles Mgone, Prof. Paul Fine, Prof. David Dunne and Dr. Jim Tartaglia. The members of the SAB bring together broad and strong expertise from the field of HIV, TB, Malaria, Parasitology and Vaccines with both academic and industrial perspective, which is invaluable to the program.

Prof. Charles Mgone

Charles Mgone is the Executive Director of the European & Developing Countries Clinical Trials Partnership (EDCTP). Prof. Mgone is a paediatrician by training and holds a PhD in Medical and Molecular Genetics. He has worked in Africa, Europe and the Pacific where he has served as advisor at international and national levels. He has considerable experience in research, health research ethics, research administration, capacity development and training, particularly in sexually transmitted infections, HIV/AIDS, malaria and other tropical diseases. Before joining EDCTP, Prof. Mgone was the Network Director of the African Malaria Network Trust (AMANET) responsible for coordinating capacity development and networking in accelerating the development and assessment of malaria vaccines and other interventions. Prior to that he was a Research Fellow at the Duncan Guthrie Institute of Medical Genetics, University of Glasgow, the Deputy Director of the Papua New Guinea Institute of Medical Research and adjunct professor of Health Research of University of Papua New Guinea, and professor of Paediatrics and Child Health at the University of Dar es Salaam, Tanzania.

Prof. Paul Fine

Paul fine is Professor of Communicable Disease Epidemiology at London School of Hygiene and Tropical Medicine. Prof. Fine’s major methodological interests have been in infection dynamics, family studies, genetics, and the evaluation of vaccines (efficacy, adverse reactions and impact), applied to a variety of infections. He directed a large epidemiological research programme (the “Karonga Prevention Study”) in Malawi from 1978-2006, concentrating at first upon leprosy, then tuberculosis, and ultimately HIV, and including demographic surveillance, vaccine evaluation, and studies of other infections in a rural population in northern Malawi. Since 1997 he has been particularly involved in issues relating to vaccine-derived polio viruses, non-specific effects of vaccines, immunological correlates of protection, and vaccine schedules.

Prof. David Dunne

David Dunne is Professor of Parasitology at the University of Cambridge. He has more than 30 years experience of different aspects of schistosomiasis research. Of particular interest over the last 20 years has been multi-disciplinary research on interactions between human schistosomiasis and other infections; and the role of IgE in human immunity. One main focus now is on understanding the regulation and effector functions of IgE in disease endemic populations, as a crucial step towards both the development of safe, effective vaccines for pathogenic helminths, and the treatment and prevention of IgE-mediated hypersensitivity diseases. Dunne is author or co-author on more than 150 scientific publications. His research in disease endemic countries is carried out in long-term partnerships with African scientists. Capacity building and sustained South-South collaboration is an important component of this research strategy. His current research projects aim to include first-class immunology sited Africa. Dunne is co-applicant for a current WT Strategic Award entitled: Infection and Immunity Research & Training for Uganda (with LSHTM, Makerere University, and Uganda Virus Research Institute); and for a WT African Institutions Strengthening Award entitled: Training Health Researchers into Vocational Excellence in East Africa (with LSHTM and 7 African institutional partners); and directs the University of Cambridge’s African research training and capacity strengthening programme.

Dr. Jim Tartaglia

Jim Tartaglia currently holds the position of Vice President, New Vaccine Project Head North America for sanofi pasteur and is based in Swiftwater. Dr. Tartaglia is an inventor on over 20 patents relating to recombinant vaccines and has authored over 125 publications in the areas of molecular virology and recombinant vaccine technology. Dr. Tartaglia has been involved in the licensure of several vaccines in the human and veterinary field and was a key figure in the HIV Thai trial, RV144 which led to first demonstration that a vaccine regimen can reduce the risk of acquisition to HIV infection.

Copyright © IDEA 2010-2014. All rights reserved.